Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study

CompletedOBSERVATIONAL
Enrollment

294

Participants

Timeline

Start Date

May 17, 2023

Primary Completion Date

September 13, 2023

Study Completion Date

September 13, 2023

Conditions
Acute Ischemic Stroke Due to Medium-vessel-occlusion
Interventions
DRUG

alteplase

Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg) with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes.

DRUG

Alteplase + possible complementary IVT with tenecteplase

Intravenous thrombolysis with alteplase (0.9 mg/kg, maximum 90 mg, with 10% of the dose given as a bolus followed by an infusion lasting 60 minutes) and depending on the MRI-2 results, an additional IVT with tenecteplase (0.25mg/kg, maximum 25 mg, with 100% of the dose given as a bolus) could be given in case of persistent occlusion and with no contraindication according to the study protocol.

Trial Locations (1)

91109

Centre Hospitalier Sud Francilien, Corbeil-Essonnes

All Listed Sponsors
lead

Centre Hospitalier Sud Francilien

OTHER

NCT05809921 - Dual IntraVenous Thrombolysis Approach (DIVA) in Patients With Medium-vessel-occlusion Strokes: a Retrospective Study | Biotech Hunter | Biotech Hunter